Emergence of an adaptive immune paradigm to explain celiac disease: a perspective on new evidence and implications for future interventions and diagnosis

References

• Ludvigsson JF, Leffler DA, Bai JC, et al. The Oslo definitions for coeliac disease and related terms. Gut. 2013;62(1):43–52.
   PubMed Web of Science ®Google Scholar
• Al-Toma A, Volta U, Auricchio R, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United Eur Gastroenterol J. 2019;7(5):583–613.
   PubMed Web of Science ®Google Scholar
• Vriezinga SL, Auricchio R, Bravi E, et al. Randomized feeding intervention in infants at high risk for celiac disease. N Engl J Med. 2014;371(14):1304–1315.
   PubMed Web of Science ®Google Scholar
• Schuppan D, Maki M, Lundin KEA, et al. A randomized trial of a transglutaminase 2 inhibitor for celiac disease. N Engl J Med. 2021;385(1):35–45.
   PubMed Web of Science ®Google Scholar
• Lahdeaho ML, Scheinin M, Vuotikka P, et al. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study. Lancet Gastroenterol Hepatol. 2019;4(12):948–959.
   PubMed Web of Science ®Google Scholar
• Daveson AJM, Popp A, Taavela J, et al. Baseline quantitative histology in therapeutics trials reveals villus atrophy in most patients with coeliac disease who appear well controlled on gluten‐free diet. GastroHep. 2020;2(1):22–30.
   Google Scholar
• Comino I, Fernandez-Banares F, Esteve M, et al. Fecal gluten peptides reveal limitations of serological tests and food questionnaires for monitoring gluten-free diet in celiac disease patients. Am J Gastroenterol. 2016;111(10):1456–1465.
   PubMed Web of Science ®Google Scholar
• Tye-Din JA, Daveson AJM, Goldstein KE, et al. Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease. BMC Med. 2020;18(1):362.
   PubMed Web of Science ®Google Scholar
• Leffler DA, Kelly CP, Green PH, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015;148(7):1311–1319 e1316.
   PubMed Web of Science ®Google Scholar
• Murray JA, Kelly CP, Green PHR, et al. No difference between latiglutenase and placebo in reducing villous atrophy or improving symptoms in patients with symptomatic celiac disease. Gastroenterology. 2017;152(4):787–798 e782.
   PubMed Web of Science ®Google Scholar
• Truitt KE, Anderson RP. Editorial: a non-dietary treatment for coeliac disease-two steps forward, one step back? Authors’ reply. Aliment Pharmacol Ther. 2019;50(8):956–957.
   PubMed Web of Science ®Google Scholar
• Daveson AJM, Tye-Din JA, Goel G, et al. Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease. Aliment Pharmacol Ther. 2020;51(2):244–252.
   PubMed Web of Science ®Google Scholar
• Goel G, Tye-Din JA, Qiao SW, et al. Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease. Sci Adv. 2019;5(8):eaaw7756.
   PubMed Web of Science ®Google Scholar
• Tye-Din JA, Daveson AJM, Ee HC, et al. Elevated serum interleukin-2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease. Aliment Pharmacol Ther. 2019;50(8):901–910.
   PubMed Web of Science ®Google Scholar
• Leffler D, Kupfer SS, Lebwohl B, et al. Development of celiac disease therapeutics: report of the third gastroenterology regulatory endpoints and advancement of therapeutics workshop. Gastroenterology. 2016;151(3):407–411.
   PubMed Web of Science ®Google Scholar
• Sollid LM, Koning F. Lack of relationship of AT1001 to zonulin and prehaptoglobin-2: clinical implications. Gut. 2020;70:2211–2212.
   PubMed Web of Science ®Google Scholar
• Jabri B, Sollid LM. T cells in celiac disease. J Immunol. 2017;198(8):3005–3014.
   PubMed Web of Science ®Google Scholar
• Lebwohl B, Sanders DS, Green PHR. Coeliac Dis. Lancet. 2018;391(10115):70–81.
   PubMed Web of Science ®Google Scholar
• D’Avino P, Serena G, Kenyon V, et al. An updated overview on celiac disease: from immuno-pathogenesis and immuno-genetics to therapeutic implications. Expert Rev Clin Immunol. 2021;17(3):269–284.
   PubMed Web of Science ®Google Scholar
• Lindfors K, Ciacci C, Kurppa K, et al. Coeliac disease. Nat Rev Dis Primers. 2019;5(1):3.
   PubMed Web of Science ®Google Scholar
• Caio G, Volta U, Sapone A, et al. Celiac disease: a comprehensive current review. BMC Med. 2019;17(1):142.
   PubMed Web of Science ®Google Scholar
• Leonard MM, Sapone A, Catassi C, et al. Celiac disease and nonceliac gluten sensitivity: a review. JAMA. 2017;318(7):647–656.
   PubMed Web of Science ®Google Scholar
• Sapone A, Bai JC, Ciacci C, et al. Spectrum of gluten-related disorders: consensus on new nomenclature and classification. BMC Med. 2012;10(1):13.
   PubMedGoogle Scholar
• Auricchio R, Troncone R. Can celiac disease be prevented? Front Immunol. 2021;12:672148.
   PubMed Web of Science ®Google Scholar
• Kivela L, Caminero A, Leffler DA, et al. Current and emerging therapies for coeliac disease. Nature reviews. Gastroenterol Hepatol. 2021;18(3):181–195.
   Google Scholar
• Khaleghi S, Ju JM, Lamba A, et al. The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate. Therap Adv Gastroenterol. 2016;9(1):37–49.
   PubMed Web of Science ®Google Scholar
• Lahdeaho ML, Kaukinen K, Laurila K, et al. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology. 2014;146(7):1649–1658.
   PubMed Web of Science ®Google Scholar
• Canestaro WJ, Edwards TC, Patrick DL. Systematic review: patient-reported outcome measures in coeliac disease for regulatory submissions. Aliment Pharmacol Ther. 2016;44(4):313–331.
   PubMed Web of Science ®Google Scholar
• Skodje GI, Sarna VK, Minelle IH, et al. Fructan, rather than gluten, induces symptoms in patients with self-reported non-celiac gluten sensitivity. Gastroenterology. 2018;154(3):529–539 e522.
   PubMed Web of Science ®Google Scholar
• Gibson PR. Editorial: inaccuracies in attribution of symptoms due to gluten-not just in those with self-reported noncoeliac gluten sensitivity. Aliment Pharmacol Ther. 2020;51(3):402–403.
   PubMed Web of Science ®Google Scholar
• Sollid LM, Jabri B. Triggers and drivers of autoimmunity: lessons from coeliac disease. Nat Rev Immunol. 2013;13(4):294–302.
   PubMed Web of Science ®Google Scholar
• Smyth DJ, Plagnol V, Walker NM, et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med. 2008;359(26):2767–2777.
   PubMed Web of Science ®Google Scholar
• Dicke WK, Weijers HA, Van De Kamer JH. Coeliac disease. II. The presence in wheat of a factor having a deleterious effect in cases of coeliac disease. Acta Paediatr. 1953;42(1):34–42.
   PubMedGoogle Scholar
• Dicke WK. Coeliac disease. Investigation of the harmful effects of certain types of cereal on patients with coeliac disease. The Netherlands: University of Utrecht; 1950.
   Google Scholar
• Anderson CM, Gracey M, Burke V. Coeliac disease. Some still controversial aspects. Arch Dis Child. 1972;47(252):292–298.
   PubMed Web of Science ®Google Scholar
• Taylor KB, Truelove SC, Thomson DL, et al. An immunological study of coeliac disease and idiopathic steatorrhoea. Serological reactions to gluten and milk proteins. Br Med J. 1961;2(5269):1727–1731.
   PubMedGoogle Scholar
• Anderson WH, Mackay IR. Gut reactions–from celiac affection to autoimmune model. N Engl J Med. 2014;371(1):6–7.
   PubMed Web of Science ®Google Scholar
• Dunne MR, Byrne G, Chirdo FG, et al. Coeliac disease pathogenesis: the uncertainties of a well-known immune mediated disorder. Front Immunol. 2020;11:1374.
   PubMed Web of Science ®Google Scholar
• Goel G, King T, Daveson AJ, et al. Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies. Lancet Gastroenterol Hepatol. 2017;2(7):479–493.
   PubMed Web of Science ®Google Scholar
• Molberg O, McAdam SN, Korner R, et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med. 1998;4(6):713–717.
   PubMed Web of Science ®Google Scholar
• Arentz-Hansen H, Korner R, Molberg O, et al. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med. 2000;191(4):603–612.
   PubMed Web of Science ®Google Scholar
• Anderson RP, Degano P, Godkin AJ, et al. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat Med. 2000;6(3):337–342.
   PubMed Web of Science ®Google Scholar
• Christophersen A, Lund EG, Snir O, et al. Distinct phenotype of CD4(+) T cells driving celiac disease identified in multiple autoimmune conditions. Nat Med. 2019;25(5):734–737.
   PubMed Web of Science ®Google Scholar
• Tye-Din JA, Stewart JA, Dromey JA, et al. Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci Transl Med. 2010;2(41):41ra51.
   PubMed Web of Science ®Google Scholar
• Bodd M, Raki M, Bergseng E, et al. Direct cloning and tetramer staining to measure the frequency of intestinal gluten-reactive T cells in celiac disease. Eur J Immunol. 2013;43(10):2605–2612.
   PubMed Web of Science ®Google Scholar
• Van De Wal Y, Kooy Y, Van Veelen P, et al. Cutting edge: selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J Immunol. 1998;161(4):1585–1588.
   PubMed Web of Science ®Google Scholar
• Osman AA, Gunnel T, Dietl A, et al. B cell epitopes of gliadin. Clin Exp Immunol. 2000;121(2):248–254.
   PubMed Web of Science ®Google Scholar
• Raki M, Fallang LE, Brottveit M, et al. Tetramer visualization of gut-homing gluten-specific T cells in the peripheral blood of celiac disease patients. Proc Natl Acad Sci USA. 2007;104(8):2831–2836.
   PubMed Web of Science ®Google Scholar
• Christophersen A, Zuhlke S, Lund EG, et al. Pathogenic T cells in celiac disease change phenotype on gluten challenge: implications for T-cell-directed therapies. Adv Sci. 2021;8:e2102778.
   Web of Science ®Google Scholar
• Dorum S, Qiao SW, Sollid LM, et al. A quantitative analysis of transglutaminase 2-mediated deamidation of gluten peptides: implications for the T-cell response in celiac disease. J Proteome Res. 2009;8(4):1748–1755.
   PubMed Web of Science ®Google Scholar
• Dorum S, Arntzen MO, Qiao SW, et al. The preferred substrates for transglutaminase 2 in a complex wheat gluten digest are Peptide fragments harboring celiac disease T-cell epitopes. PLoS One. 2010;5(11):e14056.
   PubMed Web of Science ®Google Scholar
• Hardy MY, Girardin A, Pizzey C, et al. Consistency in polyclonal T-cell responses to gluten between children and adults with celiac disease. Gastroenterology. 2015;149(6):1541–1552 e1542.
   PubMed Web of Science ®Google Scholar
• Sollid LM, Tye-Din JA, Qiao SW, et al. Update 2020: nomenclature and listing of celiac disease-relevant gluten epitopes recognized by CD4(+) T cells. Immunogenetics. 2020;72(1–2):85–88.
   PubMed Web of Science ®Google Scholar
• Vriz R, Moreno FJ, Koning F, et al. Ranking of immunodominant epitopes in celiac disease: identification of reliable parameters for the safety assessment of innovative food proteins. Food Chem Toxicol. 2021;157:112584.
   PubMed Web of Science ®Google Scholar
• Pinto-Sanchez MI, Causada-Calo N, Bercik P, et al. Safety of adding oats to a gluten-free diet for patients with celiac disease: systematic review and meta-analysis of clinical and observational studies. Gastroenterology. 2017;153(2):395–409 e393.
   PubMed Web of Science ®Google Scholar
• Arentz-Hansen H, Fleckenstein B, Molberg O, et al. The molecular basis for oat intolerance in patients with celiac disease. PLoS Med. 2004;1(1):e1.
   PubMed Web of Science ®Google Scholar
• Hardy MY, Tye-Din JA, Stewart JA, et al. Ingestion of oats and barley in patients with celiac disease mobilizes cross-reactive T cells activated by avenin peptides and immuno-dominant hordein peptides. J Autoimmun. 2015;56:56–65.
   PubMed Web of Science ®Google Scholar
• Dorum S, Steinsbo O, Bergseng E, et al. Gluten-specific antibodies of celiac disease gut plasma cells recognize long proteolytic fragments that typically harbor T-cell epitopes. Sci Rep. 2016;6:25565.
   PubMed Web of Science ®Google Scholar
• Snir O, Chen X, Gidoni M, et al. Stereotyped antibody responses target posttranslationally modified gluten in celiac disease. JCI Insight. 2017;2(17). doi:https://doi.org/10.1172/jci.insight.93961.
   Google Scholar
• Matysiak-Budnik T, Moura IC, Arcos-Fajardo M, et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med. 2008;205(1):143–154.
   PubMed Web of Science ®Google Scholar
• Schumann M, Richter JF, Wedell I, et al. Mechanisms of epithelial translocation of the alpha(2)-gliadin-33mer in coeliac sprue. Gut. 2008;57(6):747–754.
   PubMed Web of Science ®Google Scholar
• Rauhavirta T, Qiao SW, Jiang Z, et al. Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A. Clin Exp Immunol. 2011;164(1):127–136.
   PubMed Web of Science ®Google Scholar
• Rauhavirta T, Oittinen M, Kivisto R, et al. Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study. J Clin Immunol. 2013;33(1):134–142.
   PubMed Web of Science ®Google Scholar
• Iversen R, Amundsen SF, Kleppa L, et al. Evidence that pathogenic transglutaminase 2 in celiac disease derives from enterocytes. Gastroenterology. 2020;159(2):788–790.
   PubMed Web of Science ®Google Scholar
• Vader LW, de Ru A, van der Wal Y, et al. Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. J Exp Med. 2002;195(5):643–649.
   PubMed Web of Science ®Google Scholar
• Fleckenstein B, Molberg O, Qiao SW, et al. Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process. J Biol Chem. 2002;277(37):34109–34116.
   PubMed Web of Science ®Google Scholar
• Ting YT, Dahal-Koirala S, Kim HSK, et al. A molecular basis for the T cell response in HLA-DQ2.2 mediated celiac disease. Proc Natl Acad Sci USA. 2020;117(6):3063–3073.
   PubMed Web of Science ®Google Scholar
• Stamnaes J, Iversen R, Du Pre MF, et al. Enhanced B-cell receptor recognition of the autoantigen transglutaminase 2 by efficient catalytic self-multimerization. PLoS One. 2015;10(8):e0134922.
   PubMed Web of Science ®Google Scholar
• Marsh MN. Transglutaminase, gluten and celiac disease: food for thought. Transglutaminase is identified as the autoantigen of celiac disease. Nat Med. 1997;3(7):725–726.
   PubMed Web of Science ®Google Scholar
• Stamnaes J, Sollid LM. Celiac disease: autoimmunity in response to food antigen. Semin Immunol. 2015;27(5):343–352.
   PubMed Web of Science ®Google Scholar
• Dafik L, Albertelli M, Stamnaes J, et al. Activation and inhibition of transglutaminase 2 in mice. PLoS One. 2012;7(2):e30642.
   PubMed Web of Science ®Google Scholar
• Bretscher PA. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci USA. 1999;96(1):185–190.
   PubMed Web of Science ®Google Scholar
• Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008;8(4):247–258.
   PubMed Web of Science ®Google Scholar
• Christophersen A, Raki M, Bergseng E, et al. Tetramer-visualized gluten-specific CD4+ T cells in blood as a potential diagnostic marker for coeliac disease without oral gluten challenge. United Eur Gastroenterol J. 2014;2(4):268–278.
   PubMed Web of Science ®Google Scholar
• Vader W, Stepniak D, Kooy Y, et al. The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc Natl Acad Sci USA. 2003;100(21):12390–12395.
   PubMed Web of Science ®Google Scholar
• Liu E, Lee H-S, Aronsson CA, et al. Risk of pediatric celiac disease according to HLA haplotype and country. N Engl J Med. 2014;371(1):42–49.
   PubMed Web of Science ®Google Scholar
• King JA, Jeong J, Underwood FE, et al. Incidence of celiac disease is increasing over time: a systematic review and meta-analysis. Am J Gastroenterol. 2020;115(4):507–525.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245–252.
   PubMed Web of Science ®Google Scholar
• Anderson RP, van Heel DA, Tye-Din JA, et al. T cells in peripheral blood after gluten challenge in coeliac disease. Gut. 2005;54(9):1217–1223.
   PubMed Web of Science ®Google Scholar
• Abadie V, Kim SM, Lejeune T, et al. IL-15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease. Nature. 2020;578(7796):600–604.
   PubMed Web of Science ®Google Scholar
• Christophersen A, Risnes LF, Dahal-Koirala S, et al. Therapeutic and diagnostic implications of T cell scarring in celiac disease and beyond. Trends Mol Med. 2019;25(10):836–852.
   PubMed Web of Science ®Google Scholar
• Petersen J, Ciacchi L, Tran MT, et al. T cell receptor cross-reactivity between gliadin and bacterial peptides in celiac disease. Nat Struct Mol Biol. 2020;27(1):49–61.
   PubMed Web of Science ®Google Scholar
• Falta MT, Fontenot AP, Rosloniec EF, et al. Class II major histocompatibility complex-peptide tetramer staining in relation to functional avidity and T cell receptor diversity in the mouse CD4(+) T cell response to a rheumatoid arthritis-associated antigen. Arthritis Rheum. 2005;52(6):1885–1896.
   PubMedGoogle Scholar
• Dahal-Koirala S, Risnes LF, Neumann RS, et al. Comprehensive analysis of CDR3 sequences in gluten-specific T-cell receptors reveals a dominant R-motif and several new minor motifs. Front Immunol. 2021;12:639672.
   PubMed Web of Science ®Google Scholar
• Raki M, Dahal-Koirala S, Yu H, et al. Similar responses of intestinal T cells from untreated children and adults with celiac disease to deamidated gluten epitopes. Gastroenterology. 2017;153(3):787–798 e784.
   PubMed Web of Science ®Google Scholar
• Shan L, Molberg O, Parrot I, et al. Structural basis for gluten intolerance in celiac sprue. Science. 2002;297(5590):2275–2279.
   PubMed Web of Science ®Google Scholar
• Dieterich W, Esslinger B, Trapp D, et al. Cross linking to tissue transglutaminase and collagen favours gliadin toxicity in coeliac disease. Gut. 2006;55(4):478–484.
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature. 1985;314(6011):537–539.
   PubMed Web of Science ®Google Scholar
• McSorley HJ, Gaze S, Daveson J, et al. Suppression of inflammatory immune responses in celiac disease by experimental hookworm infection. PLoS One. 2011;6(9):e24092.
   PubMed Web of Science ®Google Scholar
• Nilsen EM, Lundin KE, Krajci P, et al. Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma. Gut. 1995;37(6):766–776.
   PubMed Web of Science ®Google Scholar
• Hardy MY, Goel G, Russell AK, et al. A sensitive whole blood assay detects antigen-stimulated cytokine release from CD4+ T cells and facilitates immunomonitoring in a phase 2 clinical trial of nexvax2 in coeliac disease. Front Immunol. 2021;12:661622.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745–763.
   PubMed Web of Science ®Google Scholar
• Billiau A. Interferon-gamma: biology and role in pathogenesis. Adv Immunol. 1996;62:61–130.
   PubMed Web of Science ®Google Scholar
• Boehm U, Klamp T, Groot M, et al. Cellular responses to interferon-gamma. Annu Rev Immunol. 1997;15:749–795.
   PubMed Web of Science ®Google Scholar
• Beaurepaire C, Smyth D, McKay DM. Interferon-gamma regulation of intestinal epithelial permeability. J Interferon Cytokine Res. 2009;29(3):133–144.
   PubMed Web of Science ®Google Scholar
• Nava P, Koch S, Laukoetter MG, et al. Interferon-gamma regulates intestinal epithelial homeostasis through converging beta-catenin signaling pathways. Immunity. 2010;32(3):392–402.
   PubMed Web of Science ®Google Scholar
• Kooy-Winkelaar YM, Bouwer D, Janssen GM, et al. CD4 T-cell cytokines synergize to induce proliferation of malignant and nonmalignant innate intraepithelial lymphocytes. Proc Natl Acad Sci USA. 2017;114(6):E980–E989.
   PubMed Web of Science ®Google Scholar
• Ye C, Brand D, Zheng SG. Targeting IL-2: an unexpected effect in treating immunological diseases. Signal Transduct Target Ther. 2018;3:2.
   PubMed Web of Science ®Google Scholar
• Jabri B, Abadie V. IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction. Nat Rev Immunol. 2015;15(12):771–783.
   PubMed Web of Science ®Google Scholar
• Voisine J, Abadie V. Interplay between gluten, HLA, innate and adaptive immunity orchestrates the development of coeliac disease. Front Immunol. 2021;12:674313.
   PubMed Web of Science ®Google Scholar
• Dios A, Elek R, Szabo I, et al. Gamma-gliadin specific celiac disease antibodies recognize p31-43 and p57-68 alpha gliadin peptides in deamidation related manner as a result of cross-reaction. Amino Acids. 2021;53(7):1051–1063.
   PubMed Web of Science ®Google Scholar
• Truitt KE, Daveson AJM, Ee HC, et al. Randomised clinical trial: a placebo-controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease. Aliment Pharmacol Ther. 2019;50(5):547–555.
   PubMed Web of Science ®Google Scholar
• Hoydahl LS, Richter L, Frick R, et al. Plasma cells are the most abundant gluten peptide MHC-expressing cells in inflamed intestinal tissues from patients with celiac disease. Gastroenterology. 2019;156(5):1428–1439 e1410.
   PubMed Web of Science ®Google Scholar
• Anderson RP, Goel G, Hardy MY, et al. Whole blood interleukin-2 release test to detect and characterise rare circulating gluten-specific t cell responses in coeliac disease. Clin Exp Immunol. 2021;204:321–334.
   PubMed Web of Science ®Google Scholar
• Lebreton C, Menard S, Abed J, et al. Interactions among secretory immunoglobulin A, CD71, and transglutaminase-2 affect permeability of intestinal epithelial cells to gliadin peptides. Gastroenterology. 2012;143(3):698–707.e694.
   PubMed Web of Science ®Google Scholar
• Kelly CP, Murray JA, Leffler DA, et al. TAK-101 nanoparticles induce gluten-specific tolerance in celiac disease: a randomized, double-blind, placebo-controlled study. Gastroenterology. 2021;161:66–80.e8.
   PubMed Web of Science ®Google Scholar
• Anderson RP, Jabri B. Vaccine against autoimmune disease: antigen-specific immunotherapy. Curr Opin Immunol. 2013;25(3):410–417.
   PubMed Web of Science ®Google Scholar
• Silvester JA, Graff LA, Rigaux L, et al. Symptomatic suspected gluten exposure is common among patients with coeliac disease on a gluten-free diet. Aliment Pharmacol Ther. 2016;44(6):612–619.
   PubMed Web of Science ®Google Scholar
• DePaolo RW, Abadie V, Tang F, et al. Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature. 2011;471(7337):220–224.
   PubMed Web of Science ®Google Scholar
• Du Pre MF, Kozijn AE, van Berkel LA, et al. Tolerance to ingested deamidated gliadin in mice is maintained by splenic, type 1 regulatory T cells. Gastroenterology. 2011;141(2):610–620 e612.
   PubMed Web of Science ®Google Scholar
• Christophersen A, Risnes LF, Bergseng E, et al. Healthy HLA-DQ2.5+ subjects lack regulatory and memory T cells specific for immunodominant gluten epitopes of celiac disease. J Immunol. 2016;196(6):2819–2826.
   PubMed Web of Science ®Google Scholar
• Goel G, Daveson AJM, Hooi CE, et al. Serum cytokines elevated during gluten-mediated cytokine release in coeliac disease. Clin Exp Immunol. 2020;199(1):68–78.
   PubMed Web of Science ®Google Scholar
• Fasano A, Not T, Wang W, et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet. 2000;355(9214):1518–1519.
   PubMed Web of Science ®Google Scholar
• Wang W, Uzzau S, Goldblum SE, et al. Human zonulin, a potential modulator of intestinal tight junctions. J Cell Sci. 2000;113(Pt 24):4435–4440.
   PubMed Web of Science ®Google Scholar
• Leffler DA, Kelly CP, Abdallah HZ, et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol. 2012;107(10):1554–1562.
   PubMed Web of Science ®Google Scholar
• Ajamian M, Steer D, Rosella G, et al. Serum zonulin as a marker of intestinal mucosal barrier function: may not be what it seems. PLoS One. 2019;14(1):e0210728.
   PubMed Web of Science ®Google Scholar
• Massier L, Chakaroun R, and Kovacs P, et al. Blurring the picture in leaky gut research: how shortcomings of zonulin as a biomarker mislead the field of intestinal permeability. Gut. 2021;70(9):1801–1802 .
   Google Scholar
• Sarna VK, Skodje GI, Reims HM, et al. HLA-DQ:gluten tetramer test in blood gives better detection of coeliac patients than biopsy after 14-day gluten challenge. Gut. 2018;67(9):1606–1613.
   PubMed Web of Science ®Google Scholar
• Leonard MM, Silvester JA, and Leffler D, et al. Evaluating responses to gluten challenge: a randomized, double-blind, 2-dose gluten challenge trial. Gastroenterology. 2021;160(3):720-733.
   Web of Science ®Google Scholar
• Abadie V, Jabri B. IL-15: a central regulator of celiac disease immunopathology. Immunol Rev. 2014;260(1):221–234.
   PubMed Web of Science ®Google Scholar
• Dotsenko V, Oittinen M, Taavela J, et al. Genome-wide transcriptomic analysis of intestinal mucosa in celiac disease patients on a gluten-free diet and postgluten challenge. Cell Mol Gastroenterol Hepatol. 2021;11(1):13–32.
   PubMed Web of Science ®Google Scholar
• Eckert RL, Kaartinen MT, Nurminskaya M, et al. Transglutaminase regulation of cell function. Physiol Rev. 2014;94(2):383–417.
   PubMed Web of Science ®Google Scholar
• Du Pre MF, Blazevski J, Dewan AE, et al. B cell tolerance and antibody production to the celiac disease autoantigen transglutaminase 2. J Exp Med. 2020; 217(2). doi:https://doi.org/10.1084/jem.20190860
   Google Scholar
• Ciccocioppo R, Finamore A, Mengheri E, et al. Isolation and characterization of circulating tissue transglutaminase-specific T cells in coeliac disease. Int J Immunopathol Pharmacol. 2010;23(1):179–191.
   PubMed Web of Science ®Google Scholar
• Caproni M, Capone M, Rossi MC, et al. T cell response toward tissue-and epidermal-transglutaminases in coeliac disease patients developing dermatitis herpetiformis. Front Immunol. 2021;12:645143.
   PubMed Web of Science ®Google Scholar
• Freitag T, Schulze-Koops H, Niedobitek G, et al. The role of the immune response against tissue transglutaminase in the pathogenesis of coeliac disease. Autoimmun Rev. 2004;3(2):13–20.
   PubMed Web of Science ®Google Scholar
• Kalliokoski S, Piqueras VO, Frias R, et al. Transglutaminase 2-specific coeliac disease autoantibodies induce morphological changes and signs of inflammation in the small-bowel mucosa of mice. Amino Acids. 2017;49(3):529–540.
   PubMed Web of Science ®Google Scholar
• Stamnaes J, Dorum S, Fleckenstein B, et al. Gluten T cell epitope targeting by TG3 and TG6; implications for dermatitis herpetiformis and gluten ataxia. Amino Acids. 2010;39(5):1183–1191.
   PubMed Web of Science ®Google Scholar
• Pinto-Sanchez MI, Silvester JA, and Lebwohl B, et al. Society for the study of celiac disease position statement on gaps and opportunities in coeliac disease. Nat Rev Gastroenterol Hepatol. 2021. doi:https://doi.org/10.1038/s41575-021-00511-8.
   Google Scholar
• Kurppa K, Collin P, Viljamaa M, et al. Diagnosing mild enteropathy celiac disease: a randomized, controlled clinical study. Gastroenterology. 2009;136(3):816–823.
   PubMed Web of Science ®Google Scholar
• Lundin KE, Scott H, Hansen T, et al. Gliadin-specific, HLA-DQ(alpha 1*0501,beta 1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J Exp Med. 1993;178(1):187–196.
   PubMed Web of Science ®Google Scholar
• Du Pre MF, van Berkel LA, Raki M, et al. CD62L(neg)CD38 expression on circulating CD4 T cells identifies mucosally differentiated cells in protein fed mice and in human celiac disease patients and controls. Am J Gastroenterol. 2011;106(6):1147–1159.
   PubMed Web of Science ®Google Scholar
• Zuhlke S, Risnes LF, Dahal-Koirala S, et al. CD38 expression on gluten-specific T cells is a robust marker of gluten re-exposure in coeliac disease. United Eur Gastroenterol J. 2019;7(10):1337–1344.
   PubMed Web of Science ®Google Scholar
• Rao DA, Gurish MF, Marshall JL, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 2017;542(7639):110–114.
   PubMed Web of Science ®Google Scholar
• Risnes LF, Christophersen A, Dahal-Koirala S, et al. Disease-driving CD4+ T cell clonotypes persist for decades in celiac disease. J Clin Invest. 2018;128(6):2642–2650.
   PubMed Web of Science ®Google Scholar
• Ontiveros N, Tye-Din JA, Hardy MY, et al. Ex-vivo whole blood secretion of interferon (IFN)-gamma and IFN-gamma-inducible protein-10 measured by enzyme-linked immunosorbent assay are as sensitive as IFN-gamma enzyme-linked immunospot for the detection of gluten-reactive T cells in human leucocyte antigen (HLA)-DQ2.5(+) -associated coeliac disease. Clin Exp Immunol. 2014;175(2):305–315.
   PubMed Web of Science ®Google Scholar
• Sarna VK, Lundin KEA, Morkrid L, et al. HLA-DQ-gluten tetramer blood test accurately identifies patients with and without celiac disease in absence of gluten consumption. Gastroenterology. 2018;154(4):886–896 e886.
   PubMed Web of Science ®Google Scholar
• Han A, Newell EW, Glanville J, et al. Dietary gluten triggers concomitant activation of CD4+ and CD8+ alpha beta T cells and gammadelta T cells in celiac disease. Proc Natl Acad Sci USA. 2013;110(32):13073–13078.
   PubMed Web of Science ®Google Scholar
• Jabri B, de Serre NP, Cellier C, et al. Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. Gastroenterology. 2000;118(5):867–879.
   PubMed Web of Science ®Google Scholar
• Meresse B, Chen Z, Ciszewski C, et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity. 2004;21(3):357–366.
   PubMed Web of Science ®Google Scholar
• Meresse B, Curran SA, Ciszewski C, et al. Reprogramming of CTLs into natural killer-like cells in celiac disease. J Exp Med. 2006;203(5):1343–1355.
   PubMed Web of Science ®Google Scholar
• Setty M, Discepolo V, Abadie V, et al. Distinct and synergistic contributions of epithelial stress and adaptive immunity to functions of intraepithelial killer cells and active celiac disease. Gastroenterology. 2015;149(3):681–691 e610.
   PubMed Web of Science ®Google Scholar
• Kutlu T, Brousse N, Rambaud C, et al. Numbers of T cell receptor (TCR) alpha beta+ but not of TcR gamma delta+ intraepithelial lymphocytes correlate with the grade of villous atrophy in coeliac patients on a long term normal diet. Gut. 1993;34(2):208–214.
   PubMed Web of Science ®Google Scholar
• Mayassi T, Ladell K, Gudjonson H, et al. Chronic inflammation permanently reshapes tissue-resident immunity in celiac disease. Cell. 2019;176(5):967–981 e919.
   PubMed Web of Science ®Google Scholar
• Eggesbo LM, Risnes LF, Neumann RS, et al. Single-cell TCR sequencing of gut intraepithelial gammadelta T cells reveals a vast and diverse repertoire in celiac disease. Mucosal Immunol. 2020;13(2):313–321.
   PubMed Web of Science ®Google Scholar
• Nielsen MM, Witherden DA, Havran WL. gammadelta T cells in homeostasis and host defence of epithelial barrier tissues. Nat Rev Immunol. 2017;17(12):733–745.
   PubMed Web of Science ®Google Scholar
• Fernandez-Banares F, Crespo L, Nunez C, et al. Gamma delta(+) intraepithelial lymphocytes and coeliac lymphogram in a diagnostic approach to coeliac disease in patients with seronegative villous atrophy. Aliment Pharmacol Ther. 2020;51(7):699–705.
   PubMed Web of Science ®Google Scholar
• Popp A, Taavela J, and Graziano P, et al. A new intraepithelial gammadelta T-lymphocyte marker for celiac disease classification in Formalin-Fixed Paraffin-Embedded (FFPE) duodenal biopsies. Dig Dis Sci. 2021;66(10):3352-3358 .
   Web of Science ®Google Scholar
• Tiittanen M, Westerholm-Ormio M, Verkasalo M, et al. Infiltration of forkhead box P3-expressing cells in small intestinal mucosa in coeliac disease but not in type 1 diabetes. Clin Exp Immunol. 2008;152(3):498–507.
   PubMed Web of Science ®Google Scholar
• Vorobjova T, Uibo O, Heilman K, et al. Increased FOXP3 expression in small-bowel mucosa of children with coeliac disease and type I diabetes mellitus. Scand J Gastroenterol. 2009;44(4):422–430.
   PubMed Web of Science ®Google Scholar
• Frisullo G, Nociti V, Iorio R, et al. Increased CD4+CD25+Foxp3+ T cells in peripheral blood of celiac disease patients: correlation with dietary treatment. Hum Immunol. 2009;70(6):430–435.
   PubMed Web of Science ®Google Scholar
• Gianfrani C, Levings MK, Sartirana C, et al. Gliadin-specific type 1 regulatory T cells from the intestinal mucosa of treated celiac patients inhibit pathogenic T cells. J Immunol. 2006;177(6):4178–4186.
   PubMed Web of Science ®Google Scholar
• Granzotto M, Dal Bo S, Quaglia S, et al. Regulatory T-cell function is impaired in celiac disease. Dig Dis Sci. 2009;54(7):1513–1519.
   PubMed Web of Science ®Google Scholar
• Hmida NB, Ben Ahmed M, Moussa A, et al. Impaired control of effector T cells by regulatory T cells: a clue to loss of oral tolerance and autoimmunity in celiac disease? Am J Gastroenterol. 2012;107(4):604–611.
   PubMed Web of Science ®Google Scholar
• Cook L, Munier CML, Seddiki N, et al. Circulating gluten-specific FOXP3(+)CD39(+) regulatory T cells have impaired suppressive function in patients with celiac disease. J Allergy Clin Immunol. 2017;140(6):1592–1603e1598.
   PubMed Web of Science ®Google Scholar
• Zanzi D, Stefanile R, Santagata S, et al. IL-15 interferes with suppressive activity of intestinal regulatory T cells expanded in Celiac disease. Am J Gastroenterol. 2011;106(7):1308–1317.
   PubMed Web of Science ®Google Scholar
• Ben Ahmed M, Belhadj Hmida N, Moes N, et al. IL-15 renders conventional lymphocytes resistant to suppressive functions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway. J Immunol. 2009;182(11):6763–6770.
   PubMed Web of Science ®Google Scholar
• Daveson AJM, Ee HC, Andrews JM, et al. Epitope-specific immunotherapy targeting CD4-positive T cells in celiac disease: safety, pharmacokinetics, and effects on intestinal histology and plasma cytokines with escalating dose regimens of Nexvax2 in a randomized, double-blind, placebo-controlled phase 1 study. EBioMedicine. 2017;26:78–90.
   PubMed Web of Science ®Google Scholar
• Freitag TL, Podojil JR, Pearson RM, et al. Gliadin nanoparticles induce immune tolerance to gliadin in mouse models of celiac disease. Gastroenterology. 2020;158(6):1667–1681 e1612.
   PubMed Web of Science ®Google Scholar